硫唑嘌呤用于炎症性肠病，是一种安全的替代药物吗？
Azathioprine in inflammatory bowel disease, a safe alternative?
作者信息
Tanis A A
机构信息
Department of Gastroenterology and Hepatology, Internal Medicine II, Erasmus University Hospital-Dijkzigt, Rotterdam, The Netherlands.
出版信息
Mediators Inflamm. 1998;7(3):141-4. doi: 10.1080/09629359891045.
Abstract
Azathioprine and its metabolite 6-mercaptopurine are effective in the treatment of inflammatory bowel disease. They are mostly used for reduction of the use of steroids, maintenance therapy after remission induction by cyclosporin and treatment of fistulae in Crohn's disease. Adverse effects occur in about 15% of patients. The main side effects are pancreatitis, allergic reactions, fever and bone marrow suppression. Symptoms, management and prevention are discussed. A blood monitoring schedule is suggested. Azathioprine and 6-mercaptopurine seem to be safe in pregnancy. There may be a slight increased risk for developing a non-Hodgkin's lymphoma.
摘要
硫唑嘌呤及其代谢产物6-巯基嘌呤对炎性肠病有效。它们主要用于减少类固醇的使用、环孢素诱导缓解后的维持治疗以及克罗恩病瘘管的治疗。约15%的患者会出现不良反应。主要副作用为胰腺炎、过敏反应、发热和骨髓抑制。文中讨论了症状、处理方法及预防措施。并建议了血液监测方案。硫唑嘌呤和6-巯基嘌呤在孕期似乎是安全的。患非霍奇金淋巴瘤的风险可能略有增加。
相似文献
1
Azathioprine in inflammatory bowel disease, a safe alternative?硫唑嘌呤用于炎症性肠病，是一种安全的替代药物吗？
Mediators Inflamm. 1998;7(3):141-4. doi: 10.1080/09629359891045.
2
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
3
Adverse effects of azathioprine in the treatment of inflammatory bowel disease.硫唑嘌呤在治疗炎症性肠病中的不良反应。
Rev Esp Enferm Dig. 2001 Dec;93(12):769-78.
4
Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease.6-巯基嘌呤/硫唑嘌呤对炎症性肠病患者的毒性作用
Inflamm Bowel Dis. 1998 May;4(2):116-7. doi: 10.1097/00054725-199805000-00016.
5
Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.巯嘌呤在对硫唑嘌呤不耐受的炎症性肠病患者中的耐受性和安全性。
Aliment Pharmacol Ther. 2008 Feb 1;27(3):220-7. doi: 10.1111/j.1365-2036.2007.03570.x. Epub 2007 Nov 6.
6
Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease.免疫抑制剂治疗炎症性肠病致过敏反应患者脱敏治疗。
Expert Opin Drug Saf. 2010 May;9(3):379-82. doi: 10.1517/14740330903571626.
7
[Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].[硫唑嘌呤、6-巯基嘌呤和 6-硫鸟嘌呤治疗慢性炎症性肠病。临床药理学方面]
Dtsch Med Wochenschr. 2003 Feb 21;128(8):378-85. doi: 10.1055/s-2003-37378.
8
Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience.与自身免疫性肝炎患者相比，克罗恩病患者对硫唑嘌呤早期不良反应的发生率更高：一家三级转诊中心的经验。
Am J Gastroenterol. 2005 May;100(5):1121-5. doi: 10.1111/j.1572-0241.2005.41598.x.
9
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.用硫唑嘌呤和6-巯基嘌呤治疗炎症性肠病。
Gastroenterol Clin North Am. 2004 Jun;33(2):209-34, viii. doi: 10.1016/j.gtc.2004.02.004.
10
Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.新西兰炎症性肠病患者群体中硫嘌呤类药物的不良反应。
Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):563-7. doi: 10.1002/pds.926.
引用本文的文献
1
Photodegradation of Azathioprine in the Presence of Sodium Thiosulfate.硫代硫酸钠存在下阿扎胞苷的光降解。
Int J Mol Sci. 2022 Apr 2;23(7):3975. doi: 10.3390/ijms23073975.
2
, , and genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases.日本炎症性肠病患者中的 、 和 基因变异与硫嘌呤不耐受情况
Intest Res. 2017 Jul;15(3):328-337. doi: 10.5217/ir.2017.15.3.328. Epub 2017 Jun 12.
3
Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.白细胞减少症可预测炎症性肠病和白塞病患者在硫唑嘌呤维持治疗时的缓解情况。
Dig Dis Sci. 2015 Jan;60(1):195-204. doi: 10.1007/s10620-014-3355-4. Epub 2014 Sep 20.
4
Ulcerative colitis: current treatment strategies and future prospects.溃疡性结肠炎：当前的治疗策略和未来展望。
Therap Adv Gastroenterol. 2009 Mar;2(2):99-108. doi: 10.1177/1756283X09102329.
5
Current use of immunosuppressive agents in inflammatory bowel disease patients in East China.华东地区炎症性肠病患者免疫抑制剂的当前使用情况
World J Gastroenterol. 2009 Jun 28;15(24):3055-9. doi: 10.3748/wjg.15.3055.
6
Quality of care for patients with inflammatory bowel disease in East China.中国东部炎症性肠病患者的医疗质量。
World J Gastroenterol. 2008 Jan 28;14(4):612-6. doi: 10.3748/wjg.14.612.
本文引用的文献
1
Pellagra, azathioprine and inflammatory bowel disease.糙皮病、硫唑嘌呤与炎症性肠病
Clin Exp Dermatol. 1997 Jan;22(1):44-5. doi: 10.1046/j.1365-2230.1997.1930606.x.
2
Azathioprine-induced multisystem organ failure and cardiogenic shock.
Pharmacotherapy. 1997 Jul-Aug;17(4):815-8.
3
6-MP metabolite levels: a potential guide to Crohn's disease therapy.6-巯基嘌呤代谢物水平：克罗恩病治疗的潜在指南
Gastroenterology. 1997 Aug;113(2):690-2. doi: 10.1053/gast.1997.v113.agast971130690.
4
Successful desensitization for azathioprine skin rash in a patient with severe Crohn's disease.
Dig Dis Sci. 1997 Apr;42(4):823. doi: 10.1023/a:1018828517366.
5
A controlled double blind study of azathioprine in the management of Crohn's disease.一项关于硫唑嘌呤治疗克罗恩病的对照双盲研究。
Gut. 1995 Nov;37(5):674-8. doi: 10.1136/gut.37.5.674.
6
Azathioprine hypersensitivity-like reactions--a case report and a review of the literature.硫唑嘌呤类过敏样反应——一例病例报告及文献综述
Clin Exp Dermatol. 1995 Jul;20(4):353-6. doi: 10.1111/j.1365-2230.1995.tb01343.x.
7
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.硫唑嘌呤所致炎症性肠病的骨髓毒性：27年经验总结
Gut. 1993 Aug;34(8):1081-5. doi: 10.1136/gut.34.8.1081.
8
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.炎症性肠病患者接受硫唑嘌呤治疗后的长期肿瘤发生风险。
Lancet. 1994 May 21;343(8908):1249-52. doi: 10.1016/s0140-6736(94)92150-4.
9
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.硫唑嘌呤和6-巯基嘌呤用于克罗恩病的荟萃分析
Ann Intern Med. 1995 Jul 15;123(2):132-42. doi: 10.7326/0003-4819-123-2-199507150-00009.
10
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.硫唑嘌呤静脉负荷剂量可缩短克罗恩病患者的起效时间。
Gastroenterology. 1995 Dec;109(6):1808-17. doi: 10.1016/0016-5085(95)90747-5.
Zotero 插件